CraigAnthonyPortellMD

Oncology • Charlottesville, VA

Hematologic Oncology

Associate Professor of Medicine, Division of Hematology/Oncology, University of Virginia

Join to view full profile

Dr. Portell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Portell's full profile

Already have an account?

Office
1240 Lee St
Charlottesville, VA 22908
Phone+1 434-924-9333

Fax+1 434-244-7526

Summary

Dr. Craig Portell is an oncologist in Charlottesville, VA and is affiliated with Emily Couric Clinical Cancer Center and University of Virginia Medical Center. He received his medical degree from St Louis University School of Medicine and has been in practice 11 years. He specializes in hematologic oncology and is experienced in immunotherapy, chronic lymphoid leukemia, mantle cell lymphoma, waldenstrom's macroglobulinemia, and Non-Hodgkin Lymphoma.

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2010 - 2013
Loyola University Medical CenterResidency, Internal Medicine, 2006 - 2009
Saint Louis University School of MedicineClass of 2006

Certifications & Licensure

VA State Medical License 2013 - 2026
OH State Medical License 2010 - 2014
IL State Medical License 2006 - 2011
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL Start of enrollment: 2015 Apr 01
Completed
Phase 1
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy Start of enrollment: 2017 Dec 27
Completed
Phase 2
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2018 Mar 06
Recruiting
Phase 3
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Start of enrollment: 2018 Aug 13
Completed
Phase 1, Phase 2
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2018 Jan 25
Active, not recruiting
Phase 3
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia Start of enrollment: 2019 Feb 12
Active, not recruiting
Phase 3
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2019 Jan 31
Active, not recruiting
Phase 3
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age Start of enrollment: 2020 Jan 13
Active, not recruiting
Phase 2
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma Start of enrollment: 2019 Feb 19
Completed
Phase 2
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2019 Dec 13
Active, not recruiting
Phase 2
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Start of enrollment: 2020 Aug 20
Active, not recruiting
Phase 3
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above Start of enrollment: 2022 Jul 26
Recruiting
Phase 2
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Start of enrollment: 2022 Feb 02
Recruiting
Phase 1
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Start of enrollment: 2021 Feb 19
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?
Jeffrey Lantz, Craig A Portell, Emily C Ayers
Blood Reviews. 2023-09-01
246 citations
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés
Blood. 2018-12-06
236 citations
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie
Blood. 2020-09-03

Journal Articles

The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL
Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...
Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen...
Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0405
Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cel...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

When Chemo Failed, CAR T-cell Therapy Took Away a Father’s CancerSeptember 22nd, 2022
Venetoclax with Standard Chemo-Immunotherapy Induced a High Response Rate as First-Line Treatment for Mantle Cell Lymphoma and Was Generally Well Tolerated, a PrECOG Early-Phase Trial ShowsDecember 13th, 2023